Pierre Gagnon - 12 Feb 2024 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)

Role
Chief Operating Officer
Signature
/s/ Pierre Gagnon
Issuer symbol
NKGN
Transactions as of
12 Feb 2024
Net transactions value
$0
Form type
4
Filing time
14 Feb 2024, 20:14:43 UTC
Previous filing
10 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKGN Stock Option (right to buy Award $0 +360,000 $0.000000 360,000 12 Feb 2024 Common Stock 360,000 $1.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 12, 2024, the reporting person was granted 360,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning October 1, 2023, and ending October 1, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.